View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 19, 2011

DNDi to Tackle Paediatric HIV/AIDS

The Drugs for Neglected Disease initiative (DNDi) has pledged to tackle paediatric HIV/AIDS with the launch of a new product development programme. The Swiss-based organisation will work with partners in order to create an affordable therapy for children suffering from HIV/AIDS that

By cms admin

The Drugs for Neglected Disease initiative (DNDi) has pledged to tackle paediatric HIV/AIDS with the launch of a new product development programme.

The Swiss-based organisation will work with partners in order to create an affordable therapy for children suffering from HIV/AIDS that is easy to administer, easily dispersible and better tolerated than current medication options.

DNDi’s first priority will be a first-line protease inhibitor-based regimen for use in children under three years of age that improves on current drugs, while the formula must also be compatible with tuberculosis drugs.

DNDi executive director Bernard Pécoul, speaking at the 8th International AIDS Society Conference in Rome, Italy, said that millions of children that suffer from HIV/AIDS are overlooked by research and development strategies because they do not represent a lucrative market.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology